Sacubitril/valsartan in preventing disease progression in patients with arrhythmogenic right ventricular cardiomyopathy - the ARNI-ARVC multi-site randomized trial

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease that most often manifests in young, seemingly healthy adults. The essence of the disease is the replacement of cardiomyocytes with fibrous and fatty tissue.
It is a rare disease, and in most cases, it is genetically determined. At this point, patients are treated symptomatically with antiarrhythmic drugs.
Sacubitril/valsartan is the only ARNI (angiotensin receptor-neprilysin inhibitor) drug currently available, consisting of valsartan (an angiotensin II receptor antagonist) and sacubitril.
The ARNI-ARVC study will enroll 100 patients with ARVC. Recruitment will be conducted by 9 cardiac centers in Poland. Patients will be block-randomized in a 3:2 ratio to treatment with sacubitril/valsartan or a control group.
National Institute of Cardiology

Protocol number:

EudraCT number:

Project Manager/Main Investigator:
prof. dr hab. n. med. Elżbieta Katarzyna Biernacka

Duration of the study: